Drug General Information (ID: DDIL3C18UQ)
Drug Name			Foscarnet		Drug Info		Amphotericin B (liposomal)		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antiviral Agents				Antifungal Agents
Structure

Mechanism of Foscarnet-Amphotericin B (liposomal) Interaction (Severity Level: Major)
Increased risk of hypocalcemia Click to Show/Hide Mechanism Graph
Drug Name		Foscarnet				Amphotericin B (liposomal)
Mechanism 1		Hypocalcemia				Hypocalcemia
Key Mechanism Factor 1
		Factor Name		Hypocalcemia
		Factor Description		Hypocalcemia is a low level of calcium found in a blood test. It can cause symptoms such as tingling, muscle cramps and heart rhythm problems that can range from mild to life-threatening.
Mechanism Description		Increased risk of hypocalcemia by the combination of Foscarnet and Amphotericin B (liposomal)
Increased risk of nephrotoxicity Click to Show/Hide Mechanism Graph
Drug Name		Foscarnet				Amphotericin B (liposomal)
Mechanism 2		Nephrotoxicity				Nephrotoxicity
Key Mechanism Factor 2
		Factor Name		Nephrotoxicity
		Factor Description		The combination of drugs that can induce nephrotoxicity may increase the risk of kidney injury. When kidney injury occurs, the inability to remove excess urine and waste from the body can lead to high levels of urea nitrogen, creatinine, and electrolytes (such as potassium and magnesium) in the blood.
Mechanism Description		Increased risk of nephrotoxicity by the combination of Foscarnet and Amphotericin B (liposomal)

Recommended Action
Management		The manufacturer recommends avoiding concomitant therapy unless the potential benefits outweigh the risks. Electrolyte levels and renal function of patients receiving these medications concomitantly should be monitored carefully, and dosages adjusted or discontinued if necessary.

References
1	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
2	Deray G, Martinez F, Katlama C, et al "Foscarnet nephrotoxicity: mechanism, incidence and prevention." Am J Nephrol 9 (1989): 316-21. [PMID: 2554731]
3	Farese RV Jr, Schambelan M, Hollander H, et al "Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis." Ann Intern Med 112 (1990): 955-6. [PMID: 2160217]